Inami et al., http://www.jcb.org/cgi/content/full/jcb.201102031/DC1



Figure S1. **Immunoprecipitation assays.** Each wild-type p62 and p62 T350A mutant was introduced into JHH-5_*p62*$^{-/-}$ cells. The cell lysates were immunoprecipitated with anti-FLAG or anti-p62 antibody. The resulting immunoprecipitates were subjected to SDS-PAGE and analyzed by immunoblotting with anti-p62 and anti-Keap1 antibodies. The data shown are representative of three independent experiments.

Table S1. **Hepatocellular adenoma in livers of *Atg7*-deficient mice.**

Genotype	*n*	Age (months)	Number of mice with liver tumors/total
Atg7$^{f/f}$	3	4	0/3
Atg7$^{f/f}$;Alb-*Cre*	4	4	0/4
Atg7$^{f/f}$	4	9	0/4
Atg7$^{f/f}$;Alb-*Cre*	4	9	4/4 (microtumors)
Atg7$^{f/f}$	5	12	0/5
Atg7$^{f/f}$;Alb-*Cre*	4	12	4/4
Atg7$^{f/f}$	4	14	0/4
Atg7$^{f/f}$;Alb-*Cre*	4	14	4/4
Atg7$^{f/f}$	4	16	0/4
Atg7$^{f/f}$;Alb-*Cre*	4	16	4/4

Table S2. **Characteristics of patients harboring p62 and Keap1 double-positive hepatocellular carcinomas (HCCs).**

Sex, age of tumor onset, and pathological grade	Number	p62/Keap1 double-positive HCC	%	P value
Sex (*n* = 103)				
Males	88	25	28.4	0.222
Females	15	2	13.3	
Age (*n* = 104)				
<50	45	11	24.4	0.72
≥50	59	16	27.1	
Grade of HCC (*n* = 78)				
I	8	2	25.0	0.502
I+II	16	5	31.3	
II	27	12	44.4	
II+III	16	4	25.0	
III	11	4	36.4	

Correlation analysis between p62/Keap1 immunoreactivity and sex or age was performed using array samples from Shanghai Outdo Biotech Co., Ltd, Biochain Institute, Inc. and Biomax, Inc., whereas analysis of histological grade was performed using those from Shanghai Outdo Biotech Co. only.